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Aberrant promoter hypermethylation is frequently observed in
cancer. The potential for this mechanism to contribute to tumor de-
velopment depends on whether the genes affected are repressed
because of their methylation. Many aberrantly methylated genes
play important roles in development and are bivalently marked in
ES cells, suggesting that their aberrant methylation may reﬂect de-
velopmental processes.We investigated this possibility by analyzing
promoter methylation in 19 breast cancer cell lines and 47 primary
breast tumors. In cell lines, we deﬁned 120 genes that were signif-
icantly repressed in association with methylation (SRAM). These
genes allowed the unsupervised segregation of cell lines into epi-
thelial (EPCAM+ve) and mesenchymal (EPCAM−ve) lineages. How-
ever, themethylatedgeneswere already repressed innormal cells of
the same lineage, and>90% could not be derepressed by treatment
with 5-aza-2′-deoxycytidine. The tumor suppressor genes APC and
CDH1 were among those methylated in a lineage-speciﬁc fashion.
As predicted by the epithelial nature of most breast tumors, SRAM
genes that were methylated in epithelial cell lines were frequently
aberrantly methylated in primary tumors, as were genes speciﬁcally
repressed in normal epithelial cells. An SRAM gene expression sig-
nature also correctly identiﬁed the rare claudin-low and metaplastic
tumors as having mesenchymal characteristics. Our ﬁndings impli-
cate aberrant DNA methylation as a marker of cell lineage rather
than tumor progression and suggest that, in most cases, it does
not cause the repression with which it is associated.
Aberrant CpG island methylation occurs in cancer and is im-plicated in tumor progression (1), particularly when methyl-
ation of a tumor suppressor gene appears to phenocopy the
equivalent genetic mutation. Examples include MLH1 methyla-
tion in sporadic microsatellite unstable colon cancer (2) and Rb in
retinoblastoma (3).
Several tumor suppressor genes and putative tumor suppressor
genes have been reported to bemethylated in breast cancer (4), but
in most cases, evidence for a functional role in tumorigenesis is
lacking. BRCA1, which is mutated in familial breast cancer, is
reported to bemethylated in∼10%of sporadic tumors. In BRCA1-
associated familial tumors, thewild-typeBRCA1allele is frequently
lost. One report suggested that the loss of function could occur
through methylation of the remaining wild-type allele (5), but this
ﬁnding has not been supported by subsequent, larger studies (6, 7).
Breast development begins in embryonic life when epidermal
cells of ectodermal origin project into themesenchyme underlying
the mammary ridge and form lactiferous ducts. Mammary stem
cells give rise to both the inner luminal-epithelial and the outer
“basal” myoepithelial cells of the lobulo-ductal system (8). Pri-
mary breast tumors can been subdivided into many different types
by histology and by molecular proﬁling, but most tumors are
thought to be epithelial in origin, deriving either from luminal-
epithelial cells or from their progenitors (9).
It is known that many genes de novo methylated in cancer have
“bivalent” histone marks (combined histone H3 lysine-27 and
lysine-4 trimethylation) in embryonic stem (ES) cells (10). Because
bivalently marked genes frequently have a role in development, we
asked whether cancer-associated aberrant methylation might re-
ﬂect the particular cell lineage from which a breast tumor was
derived (its ontogeny). We show that aberrant DNA methylation
occurs in genes down-regulated through normal lineage commit-
ment and that the genes affected can be used to distinguish breast
tumors of epithelial and mesenchymal lineage. We propose that
most aberrant methylation reﬂects lineage commitment rather
than tumor progression.
Results
DNA Methylation Occurs Variably Across Breast Cancer Cell Lines and
Is Associated with Gene Repression. We correlated promoter
methylation with gene expression by analyzing 19 breast cancer
cell lines on Inﬁnium arrays and combining these results with
published transcriptome data (11). Inﬁnium arrays assay the
proportion of 5-methylcytosine to total cytosine at 27,578 dif-
ferent CpG dinucleotides in >14,000 genes after bisulﬁte con-
version (12). We validated the capacity of the Inﬁnium arrays to
detect changes in DNA methylation by using DNA from wild-
type and DNA methyltransferase deﬁcient HCT116 colon cancer
cell lines (Fig. S1A). The methylation levels reported by the
arrays also corresponded well to those assayed by bisulﬁte se-
quencing, both for the individual CpGs interrogated and for
neighboring CpGs (Fig. S1 B and C). We restricted our analysis
to probes within 200 bp of transcription start sites because we
were interested in the effects of methylation on expression. As
expected, genes associated with methylated promoters were less
expressed than genes with unmethylated promoters (Fig. S1D).
To understand the factors that might be inﬂuencing methyla-
tion in the cell lines, we categorized the CpG probes into three
groups depending on their consistency of methylation across the
cell lines (Fig. 1A and Materials and Methods) and determined
the proportion of CpG island genes with each group. Most
consistently unmethylated (CU) probes (3,901 genes) were lo-
cated within CpG islands, whereas consistently methylated (CM)
probes (259 genes) were mostly located at non-CpG island
promoters (Fig. S1E). Variably methylated (VM) probes (1,023
genes) were signiﬁcantly more likely to be in CpG islands than
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CM probes (51% vs. 24%). VM genes were frequently not
expressed even when unmethylated, with 45% being unexpressed
in all 19 cell lines (Fig. S1F). However, a signiﬁcant proportion
(12%) of the VM genes did show the expected inverse relation-
ship between DNA methylation and expression (Fig. 1B).
Methylated and Variably Methylated Genes Have Tissue-Speciﬁc
Expression Patterns. We functionally characterized the gene groups
using Gene Ontology (GO) terms (Fig. S1G). CU genes were asso-
ciatedwithmetabolic or housekeeping processes, whereasCMgenes
were associated withmore specialized, lineage-restricted terms, such
as meiosis, and mast cell activation. In contrast, VM genes were
signiﬁcantly associated with general developmental processes.
Given that genes with different methylation patterns were
associated with different functions, we examined whether they
also had different patterns of expression in normal tissues by
scoring them according to their degree of tissue speciﬁcity (SI
Materials and Methods). CU genes were signiﬁcantly enriched in
genes showing a housekeeping expression pattern (Fig. 1C). In
contrast, VM genes were signiﬁcantly enriched for tissue-speciﬁc
expression. CM genes displayed a similar pattern to VM genes
but did not quite reach signiﬁcance (P = 0.065). The tissue
speciﬁcity of VM genes was also apparent when VM genes with
CpG island and non-CpG island promoters were analyzed sep-
arately (Fig. S1H).
CpGs That Are Variably Methylated in Cell Lines Are Frequently
Unmethylated in Normal Breast Tissue and Normal Mammary
Epithelial Cells. We next asked whether it was the CM or VM
probes that could be regarded as aberrantly methylated in cancer
because they were unmethylated in normal human mammary
epithelial cells (HMEC) and normal breast tissue. CU probes
were nearly always unmethylated in the normal DNA samples. A
high proportion of VM probes (58–66%) were also unmethy-
lated in these normal samples, and this was a signiﬁcantly greater
proportion than was found for the CM probes (5–7%, P < 2.2 ×
10−16, Fisher’s exact tests; Fig. 2A). As there were also ∼4 times
more VM genes (n = 1,023) than CM genes (n = 259), aberrant
methylation was signiﬁcantly more likely to occur at VM genes.
VM probes were also more likely to be unmethylated than CM
probes in a panel of nine normal tissues and in human ES (hES)
cells (Fig. S2 A and B).
VM Genes Are Enriched for “Bivalent” Histone Marks in hES Cells.
Cancer-associated aberrant methylation frequently occurs at
genes with bivalent histone marks in hES cells (histone H3K4me3
and H3K27me3; ref. 10). We noticed a striking similarity between
functional terms associated with VM genes and those previously
associated with bivalently marked genes in hES cells (Fig. S2C;
ref. 13). We used data from this study to determine the histone
marks associated with CU, CM, and VM genes in hES cells. A
signiﬁcant proportion of CU genes were marked by H3K4me3
alone (P < 2 × 10−16, Fisher’s exact test), whereas most CM and
VM genes lacked H3K4me3 and H3K27me3 (Fig. 2B). However,
the VM group was signiﬁcantly enriched for bivalent marks
(16.9% of the total; P = 7 × 10−22, Fisher’s exact test) compared
with the control. This enrichment was not seen in the CM group.
Genes That Are Signiﬁcantly Repressed in AssociationwithMethylation
(SRAM) Segregate Breast Cancer Cell Lines into Epithelial and Mesen-
chymal Lineages. As VM genes were lineage-speciﬁc, we asked
whether they could be used to categorize the cell lines according
to lineage. The expression levels of the 1,000 most variably
expressed genes segregated the 19 breast cancer cell lines into the
previously described luminal, basal A, and basal B subtypes (Fig.
3A; ref. 11). However, hierarchical clustering using methylation
levels of the 1,023 VM genes derived different groupings (Fig.
3B): Two of the basal A cell lines (MDAMB468 and HCC1954)
now clustered with the luminal cell lines. As not all VM genes
showed a good correlation with repression (Fig. 1B), we repeated
the analysis using the expression levels of those VM genes that
were signiﬁcantly repressed in association with methylation
(SRAM; 120 genes; Fig. 3C and Dataset S1). In this analysis, all
of the basal A cell lines clustered with the luminal cell lines.
Similar results were observed when we used only those SRAM
genes with CpG island promoters (67 genes; Fig. 3A).
The classiﬁcation based on SRAM genes correlated well with
cell morphology; the luminal group cells generally grew as tight
clusters typical of epithelial cells, whereas the other group
showed less cell–cell contact and were spindle-shaped (Fig. S3B).
The epithelium-like cells were all exclusively positive for the
epithelial marker EPCAM (also known as TACSTD1 and rec-
ognized by the BerEP4 antibody; Fig. 3D) and, with the excep-
tion of HCC1569, all expressed cytokeratin 19 and other markers
expressed by normal epithelial cells (Fig. 3E; ref.14). In contrast,
the other group was negative for EPCAM expression and, with
the exception of MCF10A cells, did not consistently express
keratins. However, they did express genes associated with mes-
enchyme (Fig. 3E; ref. 15). These data indicated that EPCAM−
ve cells were likely to be of mesenchymal lineage. Thus, the
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cantly negative correlation between expression and methyl-
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differential expression of SRAM genes classiﬁed breast cancer
cell lines into those of epithelial and mesenchymal lineage.
SRAM Genes Undergo Lineage-Speciﬁc Repression. Heat maps of
SRAM gene expression and methylation illustrate the striking
patterns that differentiate epithelial and mesenchymal cell lines
(Fig. 4A; larger heat maps are presented in Fig. S4A). The SRAM
gene list containsAPC,GSTP1, and PYCARD (16, 17), which have
been reported to be methylated in breast cancer, and CLDN7,
a tight junction protein expressed in epithelial cells that is methyl-
ated in some breast cancer cell lines (18). It also contains genes
that have been shown to be differentially expressed in different
subcompartments of the normal breast (for example, SPARC and
MB; refs. 19 and 20). Indeed, 71 SRAM genes are included in
published signatures of different cell populations puriﬁed from
normal breast tissue (21), a highly signiﬁcant enrichment (P=7.1×
10−16, Fisher’s exact test).
To determine whether the SRAM genes were coordinately re-
pressed in association with lineage in the normal breast, we in-
terrogated the same dataset of normal cell populations (21). SRAM
genes preferentially methylated in EPCAM+ve breast cancer cell
lines had signiﬁcantly lower levels of expression in cellular fractions
corresponding to differentiated luminal and luminal progenitor
cells (both EPCAM+ve, Wilcoxon test; Fig. 4B). In contrast, genes
methylated in EPCAM−ve breast cancer cell lines had signiﬁcantly
lower levels of expression in the basal/myoepithelial cell fraction and
even lower levels of expression in the mesenchymal stromal fraction
(both EPCAM−ve, Wilcoxon test; Fig. 4B). A similar pattern was
observed when we considered SRAM genes with CpG island and
non-CpG island promoters separately (Fig. S4B). Thus, genes prone
tomethylation in cell lines of different lineages are generally already
repressed in normal cells of the corresponding lineage.
Majority of Genes Methylated in Breast Cancer Cell Lines Are Not
Derepressed by Demethylation.As our results suggested that genes
prone to methylation might already be repressed by lineage-
speciﬁc factors, we investigated the extent to which DNA meth-
ylation might be important for their repression using the deme-
thylating agent 5-aza-2′-deoxycytidine (5-aza-dC). Treatment of
three breast cancer cell lines with 5-aza-dC led to the deme-
thylation and reexpression of DAZL, a gene whose expression is
known to be directly controlled by DNA methylation in normal
development (Fig. S4 C and D; ref. 22). The cancer testis antigen
GAGE4 was also derepressed as expected (23). We proﬁled gene
expression levels after 5-aza-dC or mock treatment using micro-
arrays, combining this with our methylation data to ascertain, in
an unbiased manner, the proportion of methylated genes that
were reactivated. Less than 10% of the silenced methylated
genes were derepressed by 5-aza-dC in the three breast cancer
lines, and derepression did not show a greater speciﬁcity for VM
genes (Fig. 4 C and D). A similar proportion of genes with
unmethylated promoters were derepressed by 5-aza-dC exposure
(Fig. 4C). Our arrays indicated that methylated CDH1 gene was
not reexpressed by 5-aza-dC in HBL100 cells; this result was
veriﬁed using quantitative RT-PCR (Fig. S4D).
As would be expected, 5-aza-dC treatments lead to signiﬁcant
but incomplete demethylation (Fig. S4C). To be sure that we
were not missing transcription effects because of inadequate de-
methylation, we took advantage of the DNA methyltransferase-
deﬁcient HCT116 DKO cells where DNA methylation is reduced
to 3–4% of that seen in wild-type (24, 25). We compared genes
reactivated in DKO cells with those reactivated by treating wild-
type HCT116 cells with 1 μM 5-aza-dC for 3 d, a dose shown to
reduce global methylation to 35% of control (26). As expected,
there was a signiﬁcant overlap in the methylated genes dere-
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Fig. 3. SRAM gene expression segregates breast cancer cell lines into cells of epithelial and mesenchymal lineage. (A–C) Dendrograms derived from un-
supervised hierarchical clustering of the cell lines based on expression of the 1,000 most variably expressed genes (A), percentage methylation of the 1,023 VM
genes (B), and expression values from a subset of genes that are SRAM (120 genes; C). The robustness of each sample’s cluster membership is shown below the
dendrogram, expressed as the percentage of permutations in which that sample grouped in its cluster (consensus clustering, see supplementary methods).
White, luminal A; gray, basal A; black, basal B (according to ref. 11). (D) The expression of EPCAM correlates with the two main clusters derived in C (P < 2.2 ×
10−16, Wilcoxon test). The cell lines are ordered based upon their expression of EPCAM. Color coding as for A–C. (E) Markers of epithelial and mesenchymal
lineages (SI Materials and Methods) are differentially expressed between the cell lines. The cell lines are ordered and color-coded as in D. Genes that were
silent in all 19 cell lines were excluded from the analysis.
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pressed by these two methods (Fig. S4E). However, despite the
fact that more methylated genes were derepressed in the DKO
cells than by 5-aza-dC treatment, this result still only represented
16.5% of methylated genes (Fig. S4F). These data suggest that
DNA methylation at promoters is not the primary mechanism
responsible for the repression of most methylated genes in cancer.
Lineage-Speciﬁc Aberrant Methylation Occurs in Primary Tumors. To
examine whether lineage-speciﬁc methylation also occurred in
primary tumors, we generated methylation proﬁles from 47 pri-
mary breast tumors. Firstly, we analyzed SRAM gene methylation
in the samples. After excluding probes that were methylated in
normal breast, SRAMprobes that weremethylated inEPCAM+ve
cell lines were signiﬁcantly more frequently methylated in primary
tumors than those speciﬁc for EPCAM−ve cell lines (Fig. 5 A and
B and Fig. S5A). A further analysis using all genes that showed
a signiﬁcant preference for methylation in EPCAM+ve or −ve cell
lines produced a similar result (Fig. S5B). Furthermore, genes that
were speciﬁcally repressed in normal luminal epithelial cells
(compared with stroma) were also signiﬁcantly more frequently
methylated in primary tumors than those genes that were active
(Fig. S5C). Within this list of genes we also found signiﬁcant
enrichments in genes previously reported to be frequently meth-
ylated in breast tumors (Table S1).
We then looked speciﬁcally at the methylation of important tu-
mor suppressor genes in breast cancer (BRCA1 andCDH1), as well
as other genes that have been frequently reported to bemethylated
and that might also be important in breast cancer biology (APC,
GSTP1, andESR1).GSTP1 andAPC are both SRAM genes meth-
ylated predominantly in EPCAM+ve cell lines (Fig. 4A) and were
frequently methylated in primary tumors (Fig. S5D). Both are
expressed in luminal progenitor cells but are down-regulated in
differentiated luminal cells, suggesting that theirmethylation could
be linked to terminal differentiation. BRCA1 displayed a similar
expressionpatternandwasmethylated toa level of>30% in4of the
47 (8.5%) primary tumors, a frequency consistent with previous
reports (27). In contrast, CDH1 and ESR1, which are both
expressed in epithelial cells, were infrequently methylated (2/47
and 0/47, respectively; Fig. S5D). The level ofCDH1methylation in
the two tumors was also comparatively low (31% and 34%). This
result is consistent with methylation rarely affecting genes that are
ordinarily expressed in that lineage. In cell lines, CDH1 methyla-
tion was speciﬁc to those with low EPCAM expression (Fig. S5D).
Our results demonstrate that primary tumors have epithelial-
speciﬁc methylation patterns. However, recent reports have sug-
gested that certain rare tumor types, claudin-low and metaplastic
tumors, might have mesenchymal characteristics (28). We tested
whether an expression signature composed of SRAM genes could
distinguish these tumors in that dataset. As predicted, most tumor
subtypes had a high EPCAM+ve score, but claudin-low and meta-
plastic tumors more closely resembled the SRAM expression
proﬁle of EPCAM−ve cell lines (Fig. 5C and Fig. S5E). Our sig-
nature was also predictive of EPCAM expression in tumors, as had
been the case for the cell lines (Fig. 5D). The expression levels of
a larger panel of marker genes further supported a mesenchymal
origin for claudin-low tumors and metaplastic tumors, although
the latter also expressed some epithelial markers (Fig. S5F).
Discussion
The methylation of CpG island promoters is a normal de-
velopmental process that is essential for repression of some
genes, such as those on the inactive X chromosome, imprinted
genes, and some tissue-speciﬁc genes (29). In cancer, many ad-
ditional promoters are both repressed and methylated. It is often
argued that methylation could also be instrumental in their re-
pression. However, our data suggest a model whereby in breast
cancer aberrant methylation occurs at genes that are already
repressed through normal lineage commitment and methylation
is generally not required for their repression (Fig. 5E). Lineage-
speciﬁc aberrant methylation has not been previously reported
but can be found in datasets of breast cancer methylation pat-
terns from a number of other studies (Table S1).
The ﬁnding that most cancer-associated aberrant methylation
occurs in genes that are already down-regulated has been alluded
to previously (30), and this phenomenon also occurs in normal
cultured neural cells (31). However, the literature contains many
examples of methylated genes being derepressed by 5-aza-dC in
cell lines, which has been central to the argument that aberrant
methylation causes tumor progression by silencing genes. In-
deed, one study assumed that in HCT116 cells, all methylated
genes are repressed because of methylation and used the amount
of deregulation induced by 5-aza-dC to estimate the size of the
methylome (5% of all genes; ref. 32). However, by using an
unbiased approach and directly measuring the proportions of
methylated and unmethylated genes that are actually dere-
pressed by 5-aza-dC, our results challenge this view. We ﬁnd that
B
Lum Lum Pro Bas Stroma
-1
-0.5
0
0.5
1
-1.5
1.5
Normal Breast Cell Type
** **
Genes Methylated in
EPCAM +ve BC Lines
Genes Methylated in
EPCAM -ve BC Lines
Lum Lum Pro Bas Stroma
Normal Breast Cell Type
-1
-0.5
0
0.5
E
xp
re
ss
io
n 
(M
ed
ia
n 
Z-
S
co
re
)
-1.5
1
1.5
** ***
A
SPARC
MB
GSTP1
APC
CLDN7
Methylation Expression
Key:
0
-4
4
Expression
Z-Score:
Methylation:
50%
0%
100%
-ve +veEPCAM -ve +veEPCAM
Cell Lines
G
en
es
Methylated Unmethylated
Methylation Status:
MCF7 BT20 HBL100
%
 G
en
es
 A
ct
iv
at
ed
 b
y 
5-
A
ZA
100
80
40
20
0
60
*
C
CM VMAll (Control)
Gene Set:
MCF7 BT20 HBL100
%
 G
en
es
 A
ct
iv
at
ed
 b
y 
5-
A
ZA
100
80
40
20
0
60
p=0.58 p=0.76 p=0.95
D
Fig. 4. In cell lines SRAM genes are repressed and methyl-
ated in a lineage-dependent manner, and most are not
controlled by DNA methylation. (A) Heat maps showing the
expression and methylation levels of SRAM genes in breast
cancer cell lines (color coded as in Fig. 3) together with their
EPCAM status. The cell lines and genes are clustered using
hierarchical clustering. See Fig. S4A for larger heat maps. (B)
Expression levels of differentially methylated SRAM genes in
different cell types in the normal breast. Lum, luminal epi-
thelial cells; Lum Pro, luminal epithelial progenitors (both
EPCAM+ve); Bas, basal myoepithelial cells; Stroma, mesen-
chymal stromal cells (both EPCAM−ve). Expression values are
median z scores, and differences between groups were
tested using Wilcoxon tests. (C) The percentages of meth-
ylated and unmethylated genes that were reactivated by 5-
aza-dC treatment in three breast cancer cell lines (Fisher’s
exact tests). (D) The percentage of CM and VM genes reac-
tivated by 5-aza-dC compared with the percentage of all
genes reactivated by 5-aza-dC. No signiﬁcant differences
were detected (χ2 tests). *P < 0.05; **P < 0.01; ***P < 0.001.
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5-aza-dC derepresses <10% of all methylated genes and that
25.5% of all genes are methylated in HCT116 cells. Repressive
histone marks may remain after treatment with 5-aza-dC (33),
indicating that DNA methylation may be one of many epigenetic
mechanisms involved in repression.
We found CDH1 and ESR1 to be rarely methylated in primary
tumors, and as these genes are expressed in epithelial cells, this
ﬁnding would be predicted by our model. Some studies using the
nonquantitative methylation-speciﬁc PCR (MSP) technique have
reported higher methylation frequencies of CDH1 and ESR1
(16, 34), including 72% in the case of CDH1 (35). However, MSP
may be prone to detecting low-level methylation at some genes. A
study using a quantitative version ofMSP agrees with our ﬁnding of
infrequentmethylationatCDH1 andESR1 (36).We foundgenuine
BRCA1 methylation in 8.5% of tumors, consistent with a previous
report (27). BRCA1 is down-regulated during terminal epithelial
differentiation, which couldmake it susceptible tomethylation.We
also note that disproportionately frequent BRCA1 methylation is
observed in metaplastic carcinomas (63% of a series of 27 tumors;
ref. 27). As these tumors appear to be mesenchymal and BRCA1 is
repressed in normal mesenchymal cells, this ﬁnding is consistent
with our model that methylation affects lineage-repressed genes.
The detection ofCDH1methylation by sensitive nonquantitative
techniques (MSP) could be due to the presence of stromal cells,
contaminating blood cells (37), or tumor cells that have undergone
epithelial-to-mesenchymal transition (EMT). The existence of
EMT is breast cancer is contentious, but it would be predicted to
down-regulateCDH1 and induce metastasis. EMTmight also lead
to CDH1 methylation under our model. However, as we did not
detect signiﬁcant CDH1 methylation, our data do not support ex-
tensive EMT in most breast tumors. A previous study also found
no differences in CDH1 expression between primary tumors and
their metastases (38). Whether EMT is responsible for the mixed
epithelial and mesenchymal characteristics in rare metaplastic
tumors (Fig. S5E) remains to be determined.
Although we observed that aberrantly methylated genes were
signiﬁcantly enriched for those that are bivalently marked in ES
cells (10), most of the affected genes lacked these marks. It is
possible, therefore, that in cancer, bivalent genes are prone to
methylation because they are lineage-speciﬁc and repressed,
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rather than because of a direct interaction of the polycomb and
DNA methylation machineries.
In summary, our data indicate that aberrant methylation is a
marker of lineage restriction in cancer. Although we cannot claim
that this ﬁnding applies to every aberrantly methylated gene, our
unbiased approach clearly demonstrates that normal developmental
repression inﬂuences whether genes become aberrantly methylated
in cancer. Our ﬁndings force a reappraisal of the likely efﬁcacy of
DNA demethylating agents in cancer therapy.
Materials and Methods
A brief summary of methods used is given below. For full details, see SI
Materials and Methods and Tables S2–S4.
Breast Cancer Cell Lines and Samples. Breast cancer cell lines were obtained
fromCancer ResearchUKorATCC.Wild-type andDKO (Dnmt1−/−, Dnmt3b−/−)
HCT116 cells were kind gifts from B. Vogelstein (24). HMECs were a gift from
E. Katz at the Edinburgh Breakthrough Breast Cancer Research Unit. SHEF-6
hES cell DNA was a gift from D. Hay (MRC Centre for Regenerative Medicine).
DNA from normal breast, fetal and adult brain, testis, liver, placenta, spleen,
blood, and colon were from Biochain, After approval by our ethical board, 47
fresh frozen unselected tumor samples were obtained through the Experi-
mental Cancer Medicine Centre in Edinburgh.
5-aza-dC Treatment. Cell lines were exposed to 1 μM5-aza-dC, refreshed every
24 h, for a total of 72 h.
Microarrays. We used Illumina Inﬁnium Human Methylation27 beadarrays
and Illumina human HT12 Expression beadarrays. All data have been sub-
mitted to the Gene Expression Omnibus (GEO) database (accession no.
GSE26990).
Bioinformatic Analyses. Bioinformatic analyses were performed using R
(version 2.9.2). Ensembl 54 (NCBI36) gene annotations were used throughout.
In cell lines unmethylated genes were deﬁned as those with ≤30% meth-
ylation and methylated ones as ≥70%. In tumor samples methylated genes
were deﬁned as those with >30% methylation due to the heterogeneity of
the samples. We deﬁned groups of genes with different methylation pat-
terns as follows: CU, unmethylated in all cell lines; CM, methylated in all cell
lines or all but one cell line; VM, methylated in at least four and unmethy-
lated in at least four cell lines. Only CpGs within 200 bp of transcription start
sites were considered in our analyses. SRAM genes were VM genes that had
signiﬁcantly lower expression when methylated (one-sided Wilcoxon test).
The speciﬁcity of a gene expression pattern was measured using a method
based on information theory (SI Materials and Methods). Datasets were
downloaded from data repositories or individual papers as appropriate.
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SI Materials and Methods
DNA Methylation Proﬁling. 500 ng of DNA was bisulﬁte-converted
(EZ DNA Methylation kit, Zymo Research), ampliﬁed, and hy-
bridized to Illumina HumanMethylation27 Beadarrays following
standard Illumina protocols. Array processing was performed at
theWellcomeTrustClinicalResearchFacility inEdinburgh.DNA
methylation data has been submitted to the Gene Expression
Omnibus (GEO) database (accession no. GSE26990).
Veriﬁcation of Illumina Inﬁnium Arrays by Bisulﬁte Sequencing. 500
ng of DNA was bisulﬁte-converted (EZ DNA Methylation kit,
Zymo Research) and then subjected to two rounds of PCR am-
pliﬁcation (35 cycles each, except DAZL primers, which were 38
cycles each) using nested primers (see Table S2 for primer se-
quences and annealing temperatures). One-tenth of the reaction
from the ﬁrst round was used in the second-round reaction. PCR
products were cloned into pGEM T-Easy (Promega) and se-
quenced from the SP6 primer. Sequencing was analyzed with the
BiQ Analyzer (1).
Expression Microarray Analysis. Total RNA was isolated from cell
lines using TRIzol (Invitrogen). RNA integrity (RIN) was assessed
using an Agilent 2100 Bioanalyzer (samples used had RIN score
of ≥9.0). RNA was ampliﬁed and biotinylated using an Illumina
TotalPrep RNA Ampliﬁcation Kit and subsequently hybridized to
Illumina human HT12 Expression BeadChips. Array processing
was performed at theWellcome Trust Clinical Research Facility in
Edinburgh. Gene expression data have been submitted to the
GEO database (accession no. GSE26990).
Quantitative RT-PCR Validation of Expression Microarray Analysis.
cDNA was prepared from 400 ng of total RNA using random
priming (Promega) and the SuperScriptII system (Invitrogen).
Quantitative RT-PCR reactions were prepared using SYBR
Green PCR Master Mix (Roche) and run under standard con-
ditions on a LightCycler 480. Primers and conditions are shown in
Table S3.
Preprocessing of Methylation Data and Gene Group Deﬁnition.
Methylation data were exported from Illumina’s Genome Stu-
dio, and beta values were converted to percentage methylation by
multiplying by 100. The detection P value was used to ﬁlter out
undetected probes from the analysis, ﬂagging them as not avail-
able (NA) values (threshold 0.01). The proﬁles of BT474s,
MCF7s, MDA-MB-468s, and MDA-MB-231s used here repre-
sent the median proﬁle of multiple biological replicates (2, 7, 2,
and 3, respectively).
In cell lines and normal tissues, probes were deﬁned as unme-
thylated when they had ≤30% methylation, partially methylated
when they had >30% and <70% methylation, and methylated
when they had ≥70% methylation. In tumors, high methylation
values were rarely observed due to heterogeneousmix of cell types
in each sample. So we deﬁned methylated probes as those that
were not unmethylated (i.e., >30% methylation). Probes were
deﬁned as aberrantly methylated if they were unmethylated in the
normal breast sample (i.e., ≤30% methylation).
We deﬁned groups of genes with different methylation patterns
as follows: consistently unmethylated (CU), unmethylated in all
cell lines; consistently methylated (CM), methylated in all cell
lines or all but one cell line; variably methylated (VM), meth-
ylated in at least four and unmethylated in at least four cell lines.
Only CpGs within 200 bp of transcription start sites were con-
sidered in our analyses. Probes were mapped to genes, and any
genes with an ambiguous status (e.g., found in both the CM and
CU lists) were removed from analysis.
Analysis of Gene Expression Data. Raw expression values were
background subtracted and normalized (average normalization)
byusing IlluminaGenomestudio.Wedeﬁnedgenes thatwere “off”
and methylated as those for which all probes were undetected on
Illumina expression arrays (detection P ≥ 0.05) and median per-
cent methylation values for Inﬁnium probes within 200 bp of the
TSS were ≥70%. The “off” and unmethylated genes had median
percent methylation values of ≤30%. Reactivated genes were
deﬁned as those that had at least one probe detected in the 5-aza-
dC sample.
Analysis of Speciﬁcity of Gene Expression. The speciﬁcity of a gene’s
expression pattern was measured by using a method based on
information theory (2). A low score indicates that a gene is uni-
formly expressed, and a high score indicates that it is expressed
speciﬁcally in one tissue. Speciﬁcities were calculated for all genes
in the genome, and then genes were divided into ﬁve equal groups
based on their ranking. The distributions of gene sets with dif-
ferent methylation patterns in breast cancer cell lines were com-
pared with those of all genes on the array using a χ2 test.
Relating Gene Expression to Methylation. To deﬁne SRAM genes,
we performed a one-sidedMann–Whitney test on each of the VM
genes. Genes were selected for which the expression values in
methylated cell lines (methylation ≥70%) was signiﬁcantly lower
than in unmethylated cell lines (≤30%) using a cutoff of P < 0.05.
This approach is similar to one that has been successfully applied
to analysis of array comparative genomic hybridization data (3).
Deﬁnition and Application of EPCAM−ve and EPCAM+ve SRAM
Expression Signatures. Signatures were deﬁned as the mean ex-
pression (as a z score) for each of the SRAM genes in EPCAM
+ve or −ve cell lines. These were applied to tumor samples by
calculating the Spearman rank correlation (Rho) between sig-
natures and scaled expression values for the individual tumors
(z-scores). A total of 69 SRAM genes were present in the tumor
dataset. High scores mean that SRAM genes that were relatively
highly expressed in EPCAM+ve vs. EPCAM−ve cell lines were
highly expressed in that particular tumor relative to the other 243
and vice versa.
Expression Panel of Epithelial and Mesenchymal Markers. Mesen-
chymal markers were taken from Herschkowitz et al. (4),
epithelial markers from Allinen et al. (5), and keratins from
Malzahn et al. (6).
Genome Annotation. All platforms used in this study were anno-
tated toEnsembl54gene IDs(NCBI36).Theannotatedpositionof
eachCpGassayedon the Inﬁniumarrayswasmapped to the closest
Ensembl gene based on transcriptional start site (TSS) location.
CpGs that ambiguously mapped to more than one gene ID were
removed from the analysis. Illumina expression probes were di-
rectly mapped to the Ensembl 54 annotation by using BLASTwith
the Ensembl cDNA and ncRNA sequence sets (ungapped align-
ment). Probes weremapped if theymatched at least one transcript
withnomore than2mismatches anddidnotmatch transcripts from
another gene with <10 mismatches. CpG island locations were
taken from those biologically deﬁned in a recent study (7).
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Public Datasets.Expression data for the breast cancer cell lines was
from Neve et al. (8). Raw data were downloaded from Array
Express (E-TABM-157) and processed by using the RMA al-
gorithm (Bioconductor affy package) and an updated annotation
(U133A, Ensembl gene CDF Version 11; ref. 9). Probe set calls
used to deﬁne silent genes were similarly generated, but by using
the MAS5 algorithm. Raw gene expression data for normal tis-
sues was from Ge et al. (10) and was similarly processed (GEO
accession no. GSE2361). Processed data describing the gene
expression patterns of cells from the normal breast was from Lim
et al. (ref. 11; GEO accession no. GSE16997). Illumina expres-
sion probes were mapped to the Ensembl annotation as above.
Mean expression values were calculated for genes with multiple
probes. Gene expression signatures for different cellular frac-
tions in the normal breast were taken from the supplemental
materials of the same study, and probes were mapped to En-
sembl genes as above. Processed expression data from breast
tumors was from Hennessy et al. (ref. 12; GEO accession no.
GSE10885). Refseq IDs for array probes were taken from GEO
and mapped to Ensembl gene IDs by using Ensembl Biomart.
Where multiple probes mapped to a single gene ID, mean values
were calculated, and those mapping to none or multiple IDs
were discarded. Clinical annotation (breast cancer subtypes) was
taken from the annotation included with the GEO series.
Data on the histone modiﬁcation status of genes in human ES
(hES) cells was from the supplementary data of Zhao et al. (13).
Locations of blocks of histone modiﬁcations were updated to
NCBI36 and assigned to genes if they were within 1 kb of a TSS.
DNA methylation data for breast tumors on the Goldengate
array were from Holm et al. (14). Processed methylation data
were taken from GEO (accession no. GSE22210), and Golden-
gate probes were mapped to gene IDs in the same manner as the
Inﬁnium probes (see above). We determined the frequency of
methylation of genes by using the median level of probes within
200 bp of TSS. Frequently aberrantly methylated genes were
deﬁned as those unmethylated (≤30% methylation) in all of the
normal samples from the study and methylated (>30% methyl-
ation) in at least 20% of the tumors (≥38 tumors). We de-
termined frequently methylated genes from Pubmeth (www.
pubmeth.org; ref. 15) by searching by cancer type for “all breast
cancer.” We excluded any genes with <100 samples analyzed and
<20% methylated. The search was conducted on July 29, 2010.
Genes commonly methylated in Hill et al. (16) were taken from
ﬁgure 1B in that study. Only those genes methylated in ≥20% of
tumors were used. The total sizes of the three lists of frequently
methylated genes were: Pubmeth, 35 genes, of which 34 were in
the Lim et al. dataset (11); Holm et al. (14), 78 genes, of which
74 were present in the Lim et al. dataset (11); and Hill et al. (16),
10 genes, of which 9 were present in the Lim et al. dataset (11).
Analysis of Gene Ontology (GO) Terms/Enrichments. To analyze
functional terms, Ensembl Biomart was used to map gene iden-
tiﬁers to Gene Ontology biological process terms (Ensembl 54).
Enrichment of speciﬁc terms in each gene list was then assessed by
using Fisher’s exact test compared with all genes present on the
Inﬁnium array. Terms that were associated with <10 genes on the
Inﬁnium arrays were excluded from the analysis.
Consensus Clustering. Hierarchical clustering was performed in R
by using the Euclidian distance and the Ward algorithm. Con-
sensus clustering was performed to estimate the robustness of
each sample (17); 500 iterations of the clustering were used to
estimate robustness in each case. The consensus clustering al-
gorithm was implemented by T.I. Simpson (University of Edin-
burgh; ref. 18).
Methylation Status of Common Tumor Suppressor Genes.We deﬁned
the methylation status of common tumor suppressor genes by
using the median methylation of probes within 200 bp of their
TSS. The numbers of probes found at each gene and their
locations relative to the TSS are shown in Table S4.
1. Bock C, et al. (2005) BiQ Analyzer: visualization and quality control for DNA
methylation data from bisulﬁte sequencing. Bioinformatics 21:4067–4068.
2. Martinez O, Reyes-Valdes MH (2008) Deﬁning diversity, specialization, and gene
speciﬁcity in transcriptomes through information theory. Proc Natl Acad Sci USA 105:
9709–9714.
3. Turner N, et al. (2010) Integrative molecular proﬁling of triple negative breast cancers
identiﬁes amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023.
4. Herschkowitz JI, et al. (2007) Identiﬁcation of conserved gene expression features
between murine mammary carcinoma models and human breast tumors. Genome
Biol 8:R76.
5. Allinen M, et al. (2004) Molecular characterization of the tumor microenvironment in
breast cancer. Cancer Cell 6:17–32.
6. Malzahn K, Mitze M, Thoenes M, Moll R (1998) Biological and prognostic signiﬁcance
of stratiﬁed epithelial cytokeratins in inﬁltrating ductal breast carcinomas. Virchows
Arch 433:119–129.
7. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD Orphan CpG
islands identify numerous conserved promoters in the mammalian genome. PLoS
Genet 6:e1001134.
8. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell 10:515–527.
9. Dai M, et al. (2005) Evolving gene/transcript deﬁnitions signiﬁcantly alter the inter-
pretation of GeneChip data. Nucleic Acids Res 33:e175.
10. Ge X, et al. (2005) Interpreting expression proﬁles of cancers by genome-wide survey
of breadth of expression in normal tissues. Genomics 86:127–141.
11. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population
for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913.
12. Hennessy BT, et al. (2009) Characterization of a naturally occurring breast cancer
subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Cancer Res 69:4116–4124.
13. Zhao XD, et al. (2007) Whole-genome mapping of histone H3 Lys4 and 27
trimethylations reveals distinct genomic compartments in human embryonic stem
cells. Cell Stem Cell 1:286–298.
14. Holm K, et al. (2010) Molecular subtypes of breast cancer are associated with
characteristic DNA methylation patterns. Breast Cancer Res 12:R36.
15. Ongenaert M, et al. (2008) PubMeth: a cancer methylation database combining text-
mining and expert annotation. Nucleic Acids Res 36:D842–D846.
16. Hill VK, et al. (2010) Identiﬁcation of 5 novel genes methylated in breast and other
epithelial cancers. Mol Cancer 9:51.
17. Monti S, Tamayo P, Mesirov J, Golub T (2003) Consensus clustering: a resampling-
based method for class discovery and visualization of gene expression microarray
data. Mach Learn 52:91–118.
18. Simpson TI, Armstrong JD, Jarman AP (2010) Merged consensus clustering to assess
and improve class discovery with microarray data. BMC Bioinformatics 11:590.
Sproul et al. www.pnas.org/cgi/content/short/1013224108 2 of 13
CA
% Methylation
1000 908070605040302010
%
 P
ro
be
s
0
10
20
30
40
50
60
70
WT HCT116
HCT116 DKO ***
0%
20%
40%
60%
80%
100%
H
C
C
15
69
H
S
57
8T
M
D
A
M
B
23
1
S
U
M
1 5
9P
T
S
U
M
1 3
15
H
B
L 1
00
M
C
F
7
M
D
A
M
B
46
8
M
D
A
M
B
45
3
B
T
47
4
S
K
B
R
3
T
47
D
Z
R
75
1
%
 M
et
hy
la
tio
n
0%
20%
40%
60%
80%
100%
H
C
C
15
69
H
S
57
8T
M
D
A
M
B
2 3
1
S
U
M
15
9P
T
S
U
M
1 3
15
H
B
L1
00
M
C
F
7
M
D
A
M
B
46
8
M
D
A
M
B
45
3
B
T
47
4
S
K
B
R
3
T
47
D
Z
R
75
1
%
 M
e t
hy
l a
t io
n
Infinium Array
Bisulfite Seq.
GSTP1 in SUM1315 (10.3%)
GSTP1 in MDA-MB-468 (70.2%)
GSTP1 in SKBR3 (82.5%)
GSTP1 in MDA-MB-231 (1.8%)
Assessed CpG
B
0%
20%
40%
60%
80%
100%
C
H
F
R
-1
C
D
H
13
C
H
F
R
-2
P
Y
C
A
R
D
M
B
T
C
F
4
M
M
P
2
G
S
T
P
1
T
P
73
-2
D
A
P
K
1
T
P
73
-2
%
 M
et
hy
la
tio
n
Infinium Array
Bisulfite Seq.
0%
20%
40%
60%
80%
100%
C
H
F
R
-1
C
D
H
13
C
H
F
R
-2
P
Y
C
A
R
D
M
B
T
C
F
4
M
M
P
2
G
S
T
P
1
T
P
73
-1
D
A
P
K
1
T
P
73
-2
%
 M
et
hy
la
t io
n
Assessed CpG
Surrounding CpGs
CHFR-2 in MCF7 (8.0%)
TP73-2 in MCF7 (94.6%)
CDH13 in MCF7 (5.0%)
TCF4 in MCF7 (74.9%)
Surrounding CpGs
Fig. S1. (Continued)
Sproul et al. www.pnas.org/cgi/content/short/1013224108 3 of 13
None Partial Full
2
4
6
8
10
12
14
MCF7
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
BT474
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MDA−MB−468
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MDA−MB−231
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
SUM159PT
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MDA−MB−453
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
SKBR3
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
ZR−75−1
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
T47D
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
SUM1315MO2
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
HS578T
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
HCC1954
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
HBL100
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
HCC1569
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MCF10A
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
BT549
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MDAMB157
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
MDAMB361
Methylation
E
xp
re
ss
io
n
None Partial Full
2
4
6
8
10
12
14
BT20
Methylation
E
xp
re
ss
io
n
*** *** *** *** *** *** *** ***
*** *** *** *** *** *** *** ***
*** *** *** *** *** *** *** ***
*** *** *** *** *** *** *** ***
*** *** *** *** *** ***
D
Fig. S1. (Continued)
Sproul et al. www.pnas.org/cgi/content/short/1013224108 4 of 13
E F
0
20
40
60
80
100
%
 o
f P
ro
be
s
Whole Array CU CM VM
CpG Island Non-CpG Island
***
0%
10%
20%
30%
40%
50%
All
(Control) CU CM VM
Consistency of Methylation
Across All Cell Lines
%
of
 G
en
es
S
ile
nt
in
 A
ll 
C
el
l L
in
es
***
***
***
G
CU
Gene Expression (1.5x10-22)
Cellular Metabolic Process (2.6x10-22)
Cellular Biopolymer Metabolic Process (6.7x10-22)
Cellular Macromolecule Metabolic Process (7.8x10-22)
Biopolymer Metabolic Process (1.3x10-22)
Proliferation/
Housekeeping
VM
Multicellular Organismal Process (4.7x10-17)
System Development (1.7x10-15)
Organ Development (2.6x10-14)
Anatomical Structure Development (4.9x10-14)
Multicellular Organismal Development (7.3x10-14)
Early
Differentiation
CM
Meiosis (8.2x10-4)
Mast Cell Activation (1.3x10-3)
Di-, Tri-valent Inorganic Cation Transport (3.5x10-3)
Hormone Secretion (5.6x10-3)
M-Phase of Meiotic Cell Cycle (5.8x10-3)
Lineage
Specification
H
Housekeeping TissueSpecific
%
 o
f G
en
es
10
20
30
40
50
0
All Promoters
Control (All Genes)
VM ***
Control (All Genes)
VM ***
CpG Island Promoters
Housekeeping TissueSpecific
0
10
20
30
40
50
Control (All Genes)
VM *
Non-CpG Island Promoters
Housekeeping TissueSpecific
0
10
20
30
40
50
Fig. S1. (A) Illumina Inﬁnium arrays can distinguish cell lines with different levels of DNA methylation. Shown is a histogram of the percentage methylation
reported by all probes on the array for HCT116 colon cancer cells and a modiﬁed version of the cell line in which the DNA methyltransferases had been
genetically knocked out (HCT116 DKOs). The distributions are signiﬁcantly different (P < 2.2 × 10−16, paired Wilcoxon test), and probes reporting a high
percentage of methylation are very rare in the HCT116 DKO cells. (B) Illumina Inﬁnium arrays reliably report methylation levels at different genes in the same
cell line. We compared the methylation levels reported for individual CpGs by the Inﬁnium arrays to either the same CpG or the mean level of the CpG and its
10 nearest neighbors by bisulﬁte sequencing at a selection of genes in MCF7 cells. Multiple CpGs are shown for some genes, and the error bars represent the
SEM for ﬁve replicates of MCF7 cells. Sequencing diagrams are shown for multiple clones for some of the genes with CpGs represented by circles. Filled circles
were unconverted by bisulﬁte treatment and are methylated. Open circles were converted and therefore unmethylated. Missing circles mean sequencing was
of a low quality across that CpG in that particular clone. CpGs assessed by the Inﬁnium array are highlighted, and the reported methylation level for that CpG
on the array is shown beside the gene name. (C) Illumina Inﬁnium arrays reliably report methylation levels across different cell lines. As for B, but the region
surrounding the transcription start site of GSTP1 was assessed in multiple cell lines. (D) Expression is inversely related to methylation in breast cancer cell lines.
The methylation levels of genes were deﬁned as none (≤30%methylation), partial (>30% and <70%methylation), or full (≥70%methylation) for each cell line
based on the median of all probes within 200 bp of transcriptional start sites. The expression levels of these groups of genes were then compared (from Neve
et al.; ref. 1). *P < 0.05, **P < 0.01, ***P < 0.001, using Wilcoxon tests. For this analysis only CpGs that were within 200 bp of a TSS were considered, and only
genes present in the gene expression data were used (6,050 genes). The methylation value for each gene was the median of all probes within 200 bp of its TSS.
(E) VM genes include CpG island and non-CpG island genes. We used a set of biologically assayed CpG islands to deﬁne CpGs on the Inﬁnium arrays as CpG
island or non-CpG island (2). We then calculated the percentage of CU, CM, and VM probes that were within CpG island genes. CM and VM probes were
compared by using a Fisher’s exact test. (F) CM and VM genes are enriched in genes silent in all breast cancer cell lines. We used expression data from the cell
lines to deﬁne silent genes as those for which expression levels were called as “absent” or not signiﬁcant above background in all 19 cell lines (from Neve et al.;
ref. 1). The proportion of genes that were silent in each of our gene groups was then calculated and plotted. Signiﬁcance was assessed by comparing the
proportions of silent genes in the gene groups with the proportion of silent genes on the entire array using Fisher’s exact tests. (G) Different methylation
patterns in breast cancer cell lines are associated with different functional groups of genes. The top ﬁve biological process GO terms signiﬁcantly enriched in
each of our gene sets is shown. Signiﬁcance was assessed using Fisher’s exact tests, and P values are shown in brackets adjacent to each term. (H) VM CpG island
genes are expressed in a tissue-speciﬁc manner. Shown are the expression patterns of VM genes in normal tissues (as in Fig. 1C) compared with all genes on the
array. The patterns for all promoters are compared with those for just CpG island or non-CpG island promoters. Signiﬁcance was assessed using χ2 tests (*P <
0.05, **P < 0.01, and ***P < 0.001).
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1. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527.
2. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet 6:e1001134.
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Fig. S2. (A) VM genes are more frequently unmethylated than CM genes in normal tissues. We deﬁned probes that were unmethylated in all nine of a panel
of nine normal tissues and analyzed their proportions in the CU, CM, and VM probe sets. CM and VM probes were compared by using Fisher’s exact tests. (B)
VM genes are more frequently unmethylated than CM genes in hES cells. The proportions of CU, CM, and VM probes that are unmethylated in hES cells are
shown. CM and VM probes were compared by using Fisher’s exact tests. (C) Functional terms associated with genes with bivalent histone marks in hES cells are
also enriched in genes that show a variable methylation pattern in breast cancer cell lines. We identiﬁed the closest GO terms to the functional terms reported
as being associated with different histone marks in hES cells in Zhao et al. (1). We then analyzed their enrichment in the sets of genes associated with different
DNA methylation patterns in breast cancer cell lines. The term reported by Zhao et al. (1) is shown, and the closest GO term ID we identiﬁed is indicated in
brackets below. P values for enriched terms were calculated by comparing the number of times a term appeared in each gene list to the number of times it
appeared on the whole array using a Fisher’s exact test. The term “segment speciﬁcation” (“early differentiation” in Zhao et al.; ref. 1), which matches
GO:0007379, was excluded from the analysis, as only three genes were found on the Inﬁnium methylation array that mapped to this term. The term “cell
communication” (“lineage speciﬁcation” in Zhao et al.; ref. 1), which matches GO:0007154, was excluded from the analysis, as no genes were found on the
Inﬁnium methylation array that mapped to this term. *P < 0.05, **P < 0.01, ***P < 0.001.
1. Zhao XD, et al. (2007) Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 1:
286–298.
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Fig. S3. (A) The relationships of cell lines are similar using only SRAM genes with CpG island promoter genes. Fig. 3C is redrawn using only SRAM genes with
CpG island promoters or SRAM genes with non-CpG island promoters. Cell lines are colored as Fig. 3 (White, luminal A; gray, basal A; and black, basal B).
Robustness was calculated by using consensus clustering. (B) Cell lines with different methylation proﬁles show different morphologies. Shown are phase
contrast images of two representative cell lines from each of the groups we observed: MCF7, an EPCAM+ve cell line with an epithelial morphology, and MDA-
MB-231, an EPCAM−ve cell line with a ﬁbroblast/spindle-cell like morphology.
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Fig. S4. This ﬁgure is an enlarged version of Fig. 4A with additional information. (A) Methylation and expression levels of SRAM genes are associated with
EPCAM status. Shown are the results of unsupervised hierarchical clustering of cell lines using SRAM genes. Cell lines are clustered based on expression values,
and genes are clustered based on methylation values. The expression values and methylation values of the SRAM genes are color coded on the ﬁgure. Ex-
pression values (Right) are z scores, and methylation data (Left) are given as percentage methylation by probe. The cell lines are also color-coded by type (top
bar: white, luminal A; gray, basal A; black, basal B). Multiple probes are shown for some genes, illustrating their concordance. Also shown is methylation data
for the same genes in normal breast tissue (Left, furthest left bar) and HMEC cells (Left, third bar from right). The rightmost sidebars on both panels show genes
that are differentially expressed (indicated in black) in different lineages from normal breast tissue in Lim et al. (1). Adjacent to this sidebar is a further bar that
Legend continued on following page
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indicates probes that are located within CpG islands in black (according to Illingworth et al.; ref. 2). (B) SRAM genes with CpG promoters that are preferentially
methylated in EPCAM+ve or −ve cell lines are also repressed in the corresponding normal lineages. Shown are reproductions of Fig. 4B but using either SRAM
genes that have CpG island promoters or those without CpG island promoters. Signiﬁcance was assessed by using Wilcoxon tests. (C) 5-aza-2’-deoxycytidine (5-
aza-dC) demethylates breast cancer cell lines. Bisulﬁte sequencing of the promoter of the DAZL gene is shown after 5-aza-dC treatment or with mock
treatment in the three breast cancer cell lines assayed for reactivation of genes by 5-aza-dC (Fig. 4 C and D). Multiple clones are shown in each panel with
methylated CpGs indicated by ﬁlled circles and unmethylated ones by open circles. Missing circles mean sequencing was of a low quality across that CpG in that
particular clone. The percentage of methylated CpGs is also shown. (D) Illumina expression arrays reliably detect the reexpression of methylated genes. Shown
are expression levels of individual genes in three breast cancer cell lines after either 5-aza-dC or mock treatment as assayed by quantitative RT-PCR (QPCR) or by
Illumina expression arrays. Where known, methylation status at that gene is indicated below each cell line. DAZL is methylated in all cell lines (see C), and its
expression is controlled by methylation in normal development (3). GAGE4 is a cancer testis antigen and thus would be expected to be reexpressed upon 5-aza-
dC treatment (4). Due to segmental duplications, we were unable to determine its methylation status in the cell lines analyzed. Both of these genes were
detected as derepressed after 5-aza-dC treatment by QPCR and array analysis. In contrast CDH1 is methylated in HBL100 cells but not the other cell lines and is
not detected as being reactivated by 5-aza-dC treatment in these cells by either platform. (E) 5-aza-dC activates a subset of genes controlled by DNA
methylation. We examined how many genes that were methylated and activated by 5-aza-dC were also activated by knocking out the DNA-
methyltransferases. The two gene lists overlapped signiﬁcantly (Fisher’s exact test: P < 2.2 × 10−16). (F) Genetic ablation of DNA methylation reactivates only
a small proportion of methylated genes. We compared the number of genes reactivated by 5-aza-dC in wild-type HCT116 cells with the number reactivated by
genetic deﬁciency of DNA methyltransferases in HCT116 DKO cells. For both comparisons the numbers of methylated and unmethylated genes are plotted. The
speciﬁcity of activation for methylated genes was tested using Fisher’s exact tests. In the DKO cells, signiﬁcantly more unmethylated genes were activated, and
with 5-aza-dC treatment signiﬁcantly more methylated genes were activated. *P < 0.05, **P < 0.01, ***P < 0.001.
1. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913.
2. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet 6:e1001134.
3. Maatouk DM, et al. (2006) DNA methylation is a primary mechanism for silencing postmigratory primordial germ cell genes in both germ cell and somatic cell lineages. Development
133:3411–3418.
4. Kumagai T, et al. (2009) Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 124:827–833.
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Fig. S5. (A) Primary tumors show differential methylation of SRAM genes preferentially methylated in EPCAM+ve and −ve cell lines. The heat map shows the
methylation frequency of differentially methylated SRAM genes in 47 primary breast tumors. Only genes that are unmethylated in the normal breast are
shown. Genes and samples are ordered by their frequency of methylation. Multiple probes are shown for some genes. This is a larger version of Fig. 5A and
includes additional data. The sidebars indicate which probes are in CpG islands (as deﬁned in Illingworth et al.; ref. 1) and the expression of each gene in
different cell types in the normal breast (2). Expression is shown as median z scores. Missing data are indicated in gray. Lum, luminal epithelial cells; Lum. Pro.,
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luminal epithelial progenitors; Basal, basal myoepithelial cells; Stroma, stromal fraction. (B) VM genes that are preferentially methylated in EPCAM+ve cell lines
are more frequently aberrantly methylated in primary tumors than those preferentially methylated in EPCAM−ve cell lines. We deﬁned a broad set of probes
variably methylated in cell lines (methylated in at least one cell line and unmethylated in at least one cell line) that showed a signiﬁcant difference in their level
of methylation between EPCAM+ve and −ve cell lines. The frequencies of methylation of these probes in primary tumors are shown separately for those genes
unmethylated in normal breast tissue and for those methylated in normal breast tissue. The number of probes in each group is indicated. Signiﬁcance was
assessed using a Wilcoxon test. (C) Genes speciﬁcally repressed in the normal luminal epithelial lineage are frequently methylated in breast tumors. We deﬁned
genes speciﬁcally repressed or activated in the luminal epithelial lineage as those with signiﬁcantly lower or higher expression in both luminal cells and luminal
progenitors compared with stromal cells (Welch’s t tests, P < 0.05; from Lim et al.; ref. 2). Genes from these two sets that were unmethylated in the normal
breast were then analyzed for their methylation frequency in primary breast tumors. Shown is a boxplot of the frequency of methylation for those genes in
each set methylated in one or more tumors. Indicated above each set is the number of genes in that set (denominator) and the number methylated in one or
more tumors (numerator). The distributions were compared by using a Wilcoxon test. (D) Known breast cancer tumor suppressor genes and putative tumor
suppressor genes show different expression patterns in normal luminal progenitor cells and differentiated luminal cells and have different rates of methylation
in tumors and tumor cell lines. Shown are the expression patterns of the indicated genes in different lineages from the normal breast (from Lim et al.; ref. 2)
derived from the median z scores, along with their methylation patterns in breast cancer cell lines and their frequency of methylation in primary tumors.
Methylation was assayed as the median percentage methylation of probes within 200 bp of each gene’s TSS. Cell lines are ordered by their EPCAM expression
level and genes by their frequency of methylation in primary tumors. (E) SRAM gene expression in claudin-low and metaplastic tumors resembles that in
EPCAM−ve cell lines. We used an SRAM gene signature to score tumors based on their similarity to EPCAM−ve breast cancer cell lines, and the scores were
compared between tumor subtypes. Claudin-low and metaplastic tumors have scores that are signiﬁcantly higher than all other subtypes (Wilcoxon tests).
Tumor subtypes: LumA, luminal A; LumB, luminal B; HER2; Bas, basal; Norm, normal like; Cldn, claudin-low; Meta, metaplastic. (F) Claudin-low and metaplastic
tumors express mesenchymal markers. Shown are the mean expression levels (as z scores) by tumor type for different sets of marker genes. Mesenchymal (Mes.)
markers were taken from Herschkowitz et al. (3); epithelial (Epi.) markers were from Allinen et al. (4), and keratins were from Malzahn et al. (5) (as in Fig. 3E).
Mesenchymal-speciﬁc genes are more highly expressed in claudin-low and metaplastic tumors, whereas epithelial and cytokeratin genes are more highly
expressed in all other tumor types. Tumor subtypes are labeled as in E. *P < 0.05, **P < 0.01, ***P < 0.001.
1. Illingworth RS, Gruenewald-Schneider U, Webb S, Kerr AR, James KD, et al. Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet 6:
e1001134.
2. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913.
3. Herschkowitz JI, et al. (2007) Identiﬁcation of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76.
4. Allinen M, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32.
5. Malzahn K, Mitze M, Thoenes M, Moll R (1998) Biological and prognostic signiﬁcance of stratiﬁed epithelial cytokeratins in inﬁltrating ductal breast carcinomas. Virchows Arch 433:
119–129.
Table S1. Genes frequently methylated in primary breast tumors are signiﬁcantly enriched in a set
of genes speciﬁcally repressed in the luminal epithelial lineage
Study Technique
No. of frequently methylated
epithelial repressed genes
(≥20% tumors) Signiﬁcance
Pubmeth (1) Mainly MSP 10 0.02
Holm et al. (2) Illumina Golden Gate 30 0.005
Hill et al. (3) MIRA with COBRA veriﬁcation 5 0.005
We assessed whether a set of genes repressed in luminal epithelial cells (see Fig. S5C) was enriched in genes
reported to be frequently methylated in breast cancer. Gene lists drawn from three different sources were all
signiﬁcantly enriched in this set of genes (using Fisher’s exact tests compared with all genes assessed).
1. Ongenaert M, et al. (2008) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36:D842–D846.
2. Holm K, et al. (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12:R36.
3. Hill VK, et al. (2010) Identiﬁcation of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 9:51.
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Table S4. Positions of CpG probes relative to the TSS for the indicated genes
Gene Ensembl ID No. of probes Probe locations relative to TSS
APC ENSG00000134982 5 −151, −82, −14, 102, 185
GSTP1 ENSG00000084207 2 −20, −10
BRCA1 ENSG00000012048 6 −82, −29, 24, 72, 85, 146
CDH1 ENSG00000039068 2 5, 8
ESR1 ENSG00000091831 1 57
Table S2. Bisulﬁte PCR primers
Primer Round Forward primer Reverse primer Annealing temp., °C
MB 1 GTATTTAGTGTATATTAGGG CAACCCTAAAACAAAATCAC 44
MB 2 GTAGGAGATATTTTTATAAG CTAAACAAACTCAATCCAAA 42
MMP2 1 GAGAGAGGTAAGTGGGGTGA CCTAATTAAAACCTACTCC 45
MMP2 2 GTAGAGGTTAGGAGTAGTAG ATAACCTAAAATTTACCC 39
TCF4 1 GAATTGTAAGTTTAGTAAAG CAATTATACTATTCTATAAC 39
TCF4 2 GGGTAGGTTAGGATGTATTT AAATATACAATTCAAATTTC 37
CDH13 1 GTAGAGAAAAGTTTAAGTTTTG TTATCCACCCACTTACAAAC 44
CDH13 2 AGTTGTTTGTTAATTTTTAG AACTCACTCCAAATCCCAAC 37
CHFR 1 GGTTATTTTTGATTTTGATTAGG CACTTTCAAAAAATACCCTCTAAC 44
CHFR 2 TTATGTTATGTTGGGGTAGAAGGG CACCCTACCCACAAACAACC 52
DAPK1 1 GTTTTTGGAGGTGGGAAAGTTG TAATAATAAAATAACAACCCC 41
DAPK1 2 ATGTGTGTAGAGAAAGGGGAG ACACCCTTTATTAAAACTAAAC 44
GSTP1 1 TTGTTTGTTTATTTTTTAGG AATTAACCCCATACTAAAAAC 37
GSTP1 2 ATTTGGGAAAGAGGGAAAGG AACTCTAAACCCCATCCCC 48
PYCARD 1 GGTTTTAGAGTTTGGAAGG TCAACTTCTACCTAAAAACC 44
PYCARD 2 GGAAGGATATGGGTTAAGTG ACATAAACCTACAAAAAATAACC 44
TP73 1 AGTTAGTTGATAGAATTAAG TCACCCCAACTAACAACAAAC 40
TP73 2 ATTAAGGGAGATGGGAAAAG CCCTACACTACAACAAAATC 46
DAZL Both GAAGAGAAAAGGAAAATTAAGAG CCTTCCTAAAACTAAAACA 50
Table S3. Quantitative RT-PCR primers
Gene Forward primer Reverse primer Annealing temp, °C
CDH GACCAAGTGACCACCTTAGA CTCCGAAGAAACAGCAAGAGC 57
DAZL ACACTGAAACTTATATGCAGCCC CGGAGGTACAACATAGCTCCTTT 57
GAGE4 ACACCTGAAGAAGGGGAACC TTCACCTCCTCTGGATTTGG 57
Other Supporting Information Files
Dataset S1 (XLS)
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